Inactive Instrument

Highlights Sorrento Therapeutics Inc Other OTC

Equities

US83587F1030

End-of-day quote Other OTC Other stock markets
- ^USD	-

Mar. 15	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT
Mar. 12	News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	Mar. 15	MT
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	Mar. 12	DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET	Mar. 12	DJ
News Highlights : Top Company News of the Day - Tuesday at 1 AM ET	Mar. 12	DJ
News Highlights : Top Company News of the Day - Monday at 11 PM ET	Mar. 11	DJ
News Highlights : Top Company News of the Day - Monday at 9 PM ET	Mar. 11	DJ
Health Care Slips on Growth Doubts -- Health Care Roundup	Feb. 26	DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET	Feb. 23	DJ
News Highlights : Top Company News of the Day - Friday at 5 PM ET	Feb. 23	DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 11 AM ET	Feb. 21	DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 7 AM ET	Feb. 21	DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 12 AM ET	Feb. 21	DJ
News Highlights : Top Financial Services News of the Day - Tuesday at 4 PM ET	Feb. 20	DJ
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million.	Nov. 02	CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	23-09-21	MT
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	23-09-20	CI
Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso	23-09-12	CI
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients	23-09-07	CI
Sorrento Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Oramed Pharmaceuticals Inc. entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.	23-08-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sorrento Therapeutics Inc Other OTC

Equities

US83587F1030

Highlights

Filters